Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kyowa Kirin CoKYKOF 88 3-Year EBITDA Growth Rate is 11.30% as of Jun. 2026, which is 122% above its 10-year median of 5.10. GuruFocus rates KYKOF with a GF Score™ of 88/100 and a GF Value™ of $12.69. The stock has 2 warning signs investors should review. Among 811 Drug Manufacturers companies, Kyowa Kirin Co ranks better than 55.61% on this metric.
During the past 12 months, Kyowa Kirin Co's average EBITDA Per Share Growth Rate was 7.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 11.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 11.90% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 5.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Kyowa Kirin Co was 17.50% per year. The lowest was -14.00% per year. And the median was 5.10% per year.
Kyowa Kirin Co (OTCPK:KYKOF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Kyowa Kirin Co 3-Year EBITDA Growth Rate Related Terms
KYKOF vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kyowa Kirin Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyowa Kirin Co 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Kyowa Kirin Co's 3-Year EBITDA Growth Rate falls into.
Kyowa Kirin Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 11.30% mean?
Kyowa Kirin Co (KYKOF) has a 3-Year EBITDA Growth Rate of 11.30% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Kyowa Kirin Co and its competitors. This is 122% above median its historical median of 5.10. According to the industry distribution chart, Kyowa Kirin Co ranks #360 out of 811 companies in the Drug Manufacturers industry, placing it in the top 44.4%.
Is Kyowa Kirin Co's 3-Year EBITDA Growth Rate too high?
Kyowa Kirin Co's current 3-Year EBITDA Growth Rate of 11.30% is 122% above median its 10-year median of 5.10. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. Kyowa Kirin Co's value of 11.30% is 28.4% above this industry median. Based on the distribution chart, Kyowa Kirin Co ranks #360 out of 811 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kyowa Kirin Co has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Kyowa Kirin Co's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kyowa Kirin Co ranks #360 out of 811 companies for 3-Year EBITDA Growth Rate. This puts Kyowa Kirin Co in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. Kyowa Kirin Co's value of 11.30% is 28.4% above this benchmark. While the company's 10-year median is 5.10 vs. the industry median of 8.80, Kyowa Kirin Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyowa Kirin Co's current 3-Year EBITDA Growth Rate of 11.30% is 28.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Kyowa Kirin Co and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyowa Kirin Co's current 3-Year EBITDA Growth Rate is 11.30%, which is 122% above median its own 10-year median of 5.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyowa Kirin Co stock overvalued right now?
Kyowa Kirin Co (KYKOF) has a current 3-Year EBITDA Growth Rate of 11.30%. The stock's GF Value™ is $12.69, compared to a current price of $14.43 — trading 13.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 11.30%, which is 122% above median its 10-year median of 5.10 and 28.4% above the Drug Manufacturers industry median of 8.80. Kyowa Kirin Co's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Kyowa Kirin Co (KYKOF), the current 3-Year EBITDA Growth Rate is 11.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyowa Kirin Co (KYKOF) Overvalued in 2026?
Based on GuruFocus' analysis, Kyowa Kirin Co stock appears to be overvalued.
The current stock price of $14.43 is trading 13.7% above its estimated GF Value™ of $12.69.
Key valuation signals for KYKOF:
3-Year EBITDA Growth Rate: 11.30% (122% above median its 10-year median of 5.10)
GF Value™: $12.69 vs. price of $14.43 (13.7% above fair value)
Industry Position: 28.4% above the Drug Manufacturers median (#360 of 811)
No single metric tells the full story. See the KYKOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
88GF Score
Get the complete analysis for KYKOF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYKOF has been successfully added to your 
